Effect of Coffee Consumption on Appetite Traits in Overweight and Obesity

Overview

The effect of coffee consumption on appetite is not clear, there are studies that show an effect on the regulation of energy intake, reducing hunger and/or increasing satiety. The purpose of this trial is to evaluate the effect of 6 mg/caffeine/kg of body weight on hunger, satiety, dietary intake, biochemical variables and ghrelin and cholecystokinin concentration in overweight and obese women.

Full Title of Study: “Effect of Coffee Consumption on Hunger, Satiety, and Appetite-regulating Hormones in Women With Overweight or Obesity”

Study Type

• Study Type: Interventional
• Study Design
  • Allocation: Randomized
  • Intervention Model: Crossover Assignment
  • Primary Purpose: Basic Science
  • Masking: None (Open Label)
• Study Primary Completion Date: May 15, 2023

Detailed Description

Randomized crossover clinical trial to be realized in women between 20 and 40 years of age with overweight or obesity and apparently healthy who reside in the city of Guadalajara, Jalisco. Their participation involves their attendance to 3 interventions, in the first one it is verified whether or not they meet the inclusion criteria, a clinical history is applied to take information on pathological history, clinical data, nutritional aspects, sociodemographic and lifestyle aspects and anthropometric measurements; then they are randomly assigned to the two types of interventions in the next two subsequent ones. In the second and third interventions (with an interval of 7 days between them), participants will attend in the follicular phase of their menstrual cycle during the experiments to avoid variability in appetite. They will arrive at the institute at 8 am after an overnight fast, consume a standard 400 kcal breakfast with a distribution of 55% carbohydrates, 30% lipids and 15% protein. along with 240 ml of coffee with 6 mg/caffeine/kg body weight or the same breakfast, but with 240 ml of water. On an empty stomach and every 30 min during the 3 h following the consumption of breakfast with the beverage, the participants recorded their level of hunger, fullness, satiety, desire to eat and prospective consumption, desire to eat specific foods: sweet, salty, fatty, tasty, and sed through visual analog scales (VAS). On an empty stomach, 30 minutes after consuming breakfast with the beverage and after 180 min, a blood sample will be taken from which serum will be obtained for glucose, total cholesterol, HDL cholesterol, LDL cholesterol, VLDL cholesterol, triglycerides, ghrelin and cholecystokinin determinations. In the first intervention, participants will be instructed to fill out a 24-hour reminder form to assess dietary intake, and will be asked to record all food and beverages consumed for 3 days prior to the two interventions. Participants will also be instructed to fill out a 24-hour post-breakfast reminder with or without coffee.

Interventions

• Other: breakfast with coffee
  • breakfast with coffee with 6 mg/caffeine/kg body weight
• Other: breakfast with water
  • breakfast with 250 mL of water

Arms, Groups and Cohorts

• Experimental: breakfast with coffee
  • 250 mL of water with 6 mg/caffeine/kg
• Placebo Comparator: breakfast with water
  • 250 mL of water

Clinical Trial Outcome Measures

Primary Measures

• Change in appetite hormones
  • Time Frame: Baseline, at 30 minutes postprandially, and at 180 minutes postprandially.
  • Measured by ELISA assay (Enzyme-Linked ImmunoSorbent Assay) according to the manufacturer’s recommendations
• Change in dietary intake
  • Time Frame: Post intervention, the following 24 hours after finishing the intervention
  • Analysis of the 24 hour dietary intake recall consumed the rest of the day after the intervention. Analyzed with the Nutritionist Pro TM Software.
• Change in appetite feelings
  • Time Frame: Baseline and in the following 180 minutes postprandially, measured every 30 minutes.
  • Hunger, fullness, satiety, desire to eat and prospective consumption are assessed with the visual analog scales (VAS). They are composed of 100 mm long lines, where at one end the term “None” or “Not at all” is placed and at the other end the term “Yes, a lot” or “As much as I have never felt”. The patient marks a point between these two extremes and quantification is done by measuring the distance from the left end of the line to the mark which is scored.
• Change in desire for specific types of food
  • Time Frame: Baseline and in the following 180 minutes postprandially, measured every 30 minutes.
  • The desire to eat specific foods: sweet, salty, fatty, tasty and thirsty, was evaluated with visual analog scales, consisting of lines in which at one end is placed the term “Yes, very much” and at the other end the term “No, not at all”. The patient marks a point between these two extremes and quantification is done by measuring the distance from the left end of the line to the mark, to which a score is given.

Secondary Measures

• Change in plasma glucose
  • Time Frame: Baseline, at 30 minutes postprandially, and at 180 minutes postprandially.
  • Peripheral blood samples were taken by a venous puncture after 12 h of fasting and at 120 min postprandial, and they were immediately centrifuged at 3500 rpm to obtain serum. The serum was separated and stored at -80 ◦C for later use. The concentration of glucose, was measured with a dry chemistry analyzer “Vitros 350 Chemistry” (Ortho-Clinical Diagnostics, Johnson & Johnson Services Inc., Rochester, NY, USA).
• Change in lipid profile: total cholesterol, triglycerides, high density lipoprotein, low-density lipoprotein, very low-density lipoprotein
  • Time Frame: Baseline, at 30 minutes postprandially, and at 180 minutes postprandially.
  • Peripheral blood samples were taken by a venous puncture after 12 h of fasting, 30 min and at 180 min postprandial, and they were immediately centrifuged at 3500 rpm to obtain serum. The serum was separated and stored at -80 ◦C for later use. The concentration of triglycerides, total cholesterol, and high-density lipoprotein cholesterol (HDL-c) cholesterol was measured with a dry chemistry analyzer Vitros 350 Chemistry (Ortho-Clinical Diagnostics, Johnson & Johnson Services Inc., Rochester, NY, USA). Low-density lipoprotein cholesterol (LDL-c) was calculated with the Friedewald formula, except when triglycerides levels were higher than 400 mg/dL. Very-low-density lipoprotein cholesterol (VLDL-c) was calculated as total cholesterol minus the sum of LDL-c + HDL-c.
• 24 hour dietary intake recall pre-intervention
  • Time Frame: Baseline
  • Analysis of the 24 hour dietary intake recall consumed the day previous to the intervention. Analyzed with the Nutritionist Pro TM Software.
• Physical activity
  • Time Frame: Baseline
  • It is evaluated with the International Physical Activity Questionnaire (IPAQ). The questionnaire allows to obtain a quantitative calculation of the MET’s (metabolic equivalents), which are a measure that expresses the energetic cost of physical activities. A higher score indicates greater physical activity. The minimum value is 3.3 MET´s /minute/week and there is no a maximum value.

Participating in This Clinical Trial

Inclusion Criteria

• Women between 20 and 40 years old – Body mass index between 25-40 kg/m2. – Regular menstrual cycle of 23-32 days in the last 3 months. – Moderate consumption of coffee (up to 4 cups per day) – Having the habit of eating breakfast – Availability of time in the morning Exclusion Criteria:

• Use of any type of contraceptives in the last three months. – Use of hypoglycemic, lipid-lowering, weight-loss, appetite altering and psychiatric medications. – Diagnosis of diabetes mellitus, hypertension, cancer, polycystic ovary syndrome, hypothyroidism, hyperthyroidism, infectious disease, renal disease, dysgeusia, and gallbladder disease. – Weight loss ≥5% of their weight in the last 6 months. – Consumption of more than 20 g of alcohol per day. – Smoking – Pregnant or breastfeeding – vegetarian or vegan

Gender Eligibility: Female

Minimum Age: 20 Years

Maximum Age: 40 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

• Lead Sponsor
  • University of Guadalajara
• Provider of Information About this Clinical Study
  • Principal Investigator: Livier Nathaly Torres Castillo, Associate Professor B – University of Guadalajara